• Company
• Tremfya reimb. expanded to psoriatic arthritis
• by Eo, Yun-Ho May 27, 2022 05:56am

• Company
• Soliris to Ultomiris...generation shift picks up speed
• by Kim, Jin-Gu May 26, 2022 05:56am

• InterView
• “Allowing safe use of JAK inhibitors over restrictions"
• by Eo, Yun-Ho May 26, 2022 05:56am

• Company
• Avastin’s Q1 sales drop sharply… future sales prospects?
• by May 25, 2022 05:47am

• Product
• The supply of Tylenol suspension has been postponed again
• by Kim JiEun May 25, 2022 05:47am

• Policy
• Xarelto's generic 15 items have been revoked
• by Lee, Hye-Kyung May 25, 2022 05:47am

• Opinion
• [Reporter’s view] What was gained and lost with COVID R&D
• by Kim, Jin-Gu May 25, 2022 05:47am

• Policy
• GSK meningococcal vaccine Bexero PFS was approved in Korea
• by Lee, Hye-Kyung May 25, 2022 05:47am

• Company
• Yuhan Leclaza's first-quarter sales were 3.2 billion won
• by Chon, Seung-Hyun May 24, 2022 05:55am

• Company
• Duodart may be prescribed at general hospitals in Korea
• by Eo, Yun-Ho May 24, 2022 05:55am